Gitterman Wealth Management’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
FP
TP
Gitterman Wealth Management's MRNA Position: Q1 2022 in Review
Gitterman Wealth Management sold out of Moderna (MRNA) in Q1 2022, closing a stake of 904 shares — an estimated $234K sold.
Gitterman Wealth Management first reported a position in MRNA in Q3 2021 and held it in 2 quarters. The position peaked at $300K in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.
- Gitterman Wealth Management reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
- Gitterman Wealth Management sold 904 Moderna shares in Q1 2022, an estimated $234K.
- Gitterman Wealth Management first reported a position in Moderna in Q3 2021 and held it in 2 quarters.
- Gitterman Wealth Management's Moderna position peaked at $300K in Q3 2021.
- 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.
Based on Gitterman Wealth Management's 13F filing for Q1 2022, filed 12 May 2022.